Adagio Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $662,683,000 last year. Net change in cash is therefore $427,236,000.
Cash Flow
| 2021 | -184.73M | -50.71M | 662.68M |
|---|
ADGI Cash Flow Statement (2021 – 2021)
| 2021 | |
|---|---|
Cash at beginning of period | 114.98M |
Operating activities | |
Net income | -226.79M |
| Adjustments to reconcile net income to cash generated by operating activities: | |
Depreciation and amortization | 1.43M |
Stock-based compensation expense | 17.76M |
| Deferred income tax benefit | 17.76M |
| Changes in operating assets and liabilities: | |
Accounts receivable, net | 0 |
Inventories | 0 |
Accounts payable | -2.37M |
Cash generated by operating activities | -184.73M |
Investing activities | |
Purchases Of Investments | -188.62M |
Investments In Property Plant And Equipment | -84K |
Acquisitions Net | 0 |
Cash generated by investing activities | -50.71M |
Financing activities | |
Common Stock Issued | 335.16M |
Payments for dividends | 0 |
Repurchases of common stock | 0 |
Repayments of term debt | 0 |
Cash used in financing activities | 662.68M |
Net Change In Cash | 427.23M |
Cash at end of period | 542.22M |
| Data source |